Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Johnson & Johnson | CAPLYTA (Lumateperone) - (Study 501) | Major depressive disorder (MDD) | Phase 3 | Data Released | Oral | Psychiatric |
| Johnson & Johnson | ARX788 (ACE-Breast-02) | HER2-positive metastatic breast cancer | Phase 3 | intravenous | Oncology | |
| Johnson & Johnson | JNJ-78436735 (Ad26.COV2-S) - (ENSEMBLE-2) | COVID-19 vaccine - two-dose regimen | Phase 3 | Intramuscular | COVID-19 | |
| Johnson & Johnson | CAPLYTA (Lumateperone) - (Study 403) | Bipolar Depression and Major depressive disorder (MDD) | Phase 3 | Data Released | Oral | Psychiatric |
| Johnson & Johnson | CAPLYTA (Lumateperone) - Monotherapy (Study 404) | Bipolar depression | Phase 3 | Data Released | Oral | Psychiatric |
| Johnson & Johnson | CAPLYTA (lumateperone) - (Study 501) | Major depressive disorder (MDD) | Phase 3 | Data Released | Oral | Psychiatric |
| Johnson & Johnson | HVTN 706/HPX3002 (Mosaico) | HIV in MSM and Transgender | Phase 3 | Intramuscular | Anti-HIV | |
| Johnson & Johnson | ZYTIGA (abiraterone acetate) - (PEACE1) | Prostate Cancer | Phase 3 | Oral | Oncology |
